The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 310.00
Bid: 307.00
Ask: 312.00
Change: 0.00 (0.00%)
Spread: 5.00 (1.629%)
Open: 311.00
High: 314.00
Low: 303.00
Prev. Close: 310.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Hutchison China Drug Application Accepted

Thu, 17th Sep 2020 21:35

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Hutchison China Meditech Ltd - China-based biopharmaceutical company - New drug application for surufatinib as a treatment for advanced pancreatic neuroendocrine tumours accepted for review by China National Medical Products Administration. Application supported by data from its Sanet-p phase 3 study in China.

----------

Securities Trust of Scotland PLC - Edinburgh-based investor - Appoints Troy Asset Management Ltd as investment manager with no change to investment objective. Portfolio to be managed by Tomasz Boniek and wider Troy team. Troy to waive management fee for 12 month and make ongoing contribution to cost of secretarial and administration services. Discount control mechanism to be introduced in order to protect shareholders from company trading at discount to net asset value.

----------

FIH Group PLC - Falkland Islands-based conglomerate - Maintains focus on cash management, with cash as at August end GBP14.1 million. Trading has been hurt by Co As lockdown eases, revenue in both businesses steadily recovers but is still well below prior year levels with "significant loss of revenue in both UK businesses" from Covid-19. Not proposing interim dividend after cancelling financial 2020 dividend. "We still expect to record a loss for the financial year, though, before the costs of redundancies, at a lower underlying level than when we reported to shareholders in June." At its AGM, resolution 8 - which relates to "the disapplication of pre-emption rights, to allot equity securities or sell treasury shares for cash without first offering them to existing shareholders, in circumstances other than for a specific acquisition or capital investment" - fails to pass as does not get required 75% of votes. Board to consult with shareholders to understand and seek to address concerns.

----------

Eden Research PLC - biopesticides and plastic-free formulation technology company - Collaborator Eastman Chemical Co gets authorisation to tell Cedroz in France. Cedroz is Eden's bionematicide, targeting free living parasitic worms called nematodes. French regulator also approves its Mevalone biofungicide for use in organic agriculture in France. Mevalone also gets authorisation for use on tale and wine grapes in Serbia through regional distributor K&N Efthymiadis. Mevalone is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops.

----------

ADM Energy PLC - natural resources investor with assets in Nigeria - Formerly submits bid with Nigerian Department of Petroleum Resources for marginal field in 2020 marginal field bid round. 57 marginal fields available to participating companies and ADM is participating in the bid round as strategic partner of OilBank International Ltd. "The company expects the bid round to be concluded by the end of Q4 2020 and will update the market in due course."

----------

Dev Clever Holdings PLC - software and technology group based in Tamworth - Signs three-year commercial partnership with mobile pool betting applications provider Low6. Partnership allow for full integration of Low6's 'PubWars' mobile quiz based pool betting app to be integrated with Dev Clever's Engage gamification platform and 'PubPal' service.Partnership to be funded by fee of GBP115,000 paid to Dev Celevr by Low6 plus ongoing revenue share.

----------

Beowulf Mining PLC - miner with projects in Finland, Sweden, and Kosovo - Notes findings of market assessment of Kallak North by Bo Arvidson. Highlights of assessment include that Kallak ore testwork "has produced an exceptionally high-grade magnetite concentrate" at 71.5% iron content plus only "minimal detrimental components". This makes Kallak the market leading high-grade product within all known and planned future producers. CEO Kurt Budge: "Benchmark iron ore prices climbed to around USD130 a dry metric tonne in late August, the highest level since 2014, and with prices set to remain strong for the remainder of the year, now is the time for the Swedish government to give Kallak the 'green light'."

----------

Prairie Mining Ltd - Poland-focused coal development firm - Receives valid application for small oversubscription of 16.1 million shares at AUD0.25 issued price, raising AUD4.0 million or around GBP2.3 million. Prairie to accept all valid application with no scale back.

----------

Cadence Minerals PLC - London-based mineral resources investment company - Notes first set of results from Hastings Technology Metals, its joint venture partner in the Yangibana rare earth project in Western Australia. First nine holes all hit economic mineralisation. Hastings COO Andrew Reid: "These results have exceeded our expectations, which are an excellent first step in defining what appears to be a significant new zone of mineralisation. With this initial shallow program, we have confirmed the presence of broad mineralised widths and extended known extents of Mineral Resources. All the deepest holes confirm mineralisation continues at depth." Cadence owns 30% of Yangibana, while Hastings owns the other 70%.

----------

Galileo Resources PLC - miner with projects in Botswana, Zambia and South Africa - Begins helicopter-borne electromagnetic survey over two of its tenures within its Kalahari Copper Belt project, Botswana. Preliminary results expected by end of October. CEO Colin Bird: "Our initial activities will be two-fold in that we will investigate an area to the northeast which shows good geophysical potential and an area in the midst of a recent discovery. I have no doubt that time will see the Kalahari Copper Belt region emerging as a significant copper producer, since it already hosts two new world class deposits."

----------

Pan African Resources PLC - African-focused gold producer - Remuneration committee recommends restructuring some its long-term incentive schemes in order to simplify and consolidate, improving retention capability. CEO, financial director, and other executives and prescribed officers agree to relinquish share options under current scheme. In lieu of the relinquishment, restricted B class shares in capital of OAR Gold Prop Ltd will be issues in terms of newly established B-share scheme. Pan African owns 49% share capital of PAR Gold.

----------

Highland Gold Mining Ltd - Russian gold miner - Fortiana Holdings Ltd gets regulatory clearance from Russian Federal Antimonopoly Service in connection with its mandatory cash offer for Highland Gold. Fortiana is to acquire 145.8 million shares in Highland Gold from eight shareholders at GBP3.00 each for a total of GBP437.4 million, giving Fortiana a 40% stake in Highland and valuing the whole company at GBP1.09 billion. It has also put forward an offer to acquire all Highland shares at the same price.

----------

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
18 Apr 2023 09:55

Hutchmed gets Chinese approval for fruquintinib new drug application

(Alliance News) - Hutchmed (China) Ltd on Tuesday said the China National Medical Products Administration accepted its new drug application for fruquintinib in combination with paclitaxel.

Read more
4 Apr 2023 13:56

Hutchmed to start registration phase enrolments for two treatments

(Alliance News) - Hutchmed China Ltd on Tuesday said it will start registration phase enrolments for two of its prospective treatments under study, HMPL-453 and savolitinib.

Read more
31 Mar 2023 13:47

Hutchmed completes rolling FDA submission for colorectal cancer drug

(Sharecast News) - Pharmaceuticals developer Hutchmed China announced the completion of its rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for its oral inhibitor 'fruquintinib'.

Read more
31 Mar 2023 12:15

Hutchmed submits new drug application to US FDA for cancer treatment

(Alliance News) - Hutchmed (China) Ltd on Friday said it has completed the rolling submission of a new drug application for its fruquintinib cancer drug to the US Food & Drug Administration.

Read more
14 Mar 2023 14:23

Hutchmed China inks global licensing deal with Takeda on fruquintinib

(Alliance News) - Hutchmed China Ltd on Tuesday said it closed a license agreement with a subsidiary of Tokyo-based drug maker Takeda Pharmaceutical Co Ltd for fruquintinib.

Read more
8 Mar 2023 14:07

DIRECTOR DEALINGS: Hutchmed CFO banks GBP4 million; Haleon chair buys

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Tuesday and Wednesday and not separately reported by Alliance News:

Read more
28 Feb 2023 11:43

Hutchmed expects revenue climb from oncology, immunology division

(Alliance News) - Hutchmed (China) Ltd expects a sharp rise in revenue from its oncology and immunology-focused arm, as the biopharmaceutical firm looks forward to a productive 2023.

Read more
27 Feb 2023 11:39

Hutchmed enrols last patient in lymphoma treatment trial

(Sharecast News) - Hutchmed China announced the completion of patient enrollment in a phase two registration trial of 'amdizalisib' on Monday, for the treatment of relapsed or refractory follicular lymphoma (FL), which is a subtype of non-Hodgkin's lymphoma.

Read more
27 Feb 2023 11:11

Hutchmed completes patient enrolment for trial testing cancer therapy

(Alliance News) - Hutchmed (China) Ltd on Monday said that it has completed patient enrolment for the Phase Two registration trial of amdizalisib, its once-a-day oral monotherapy in patients with relapsed or refractory follicular lymphoma.

Read more
21 Feb 2023 15:49

UK earnings, trading statements calendar - next 7 days

Wednesday 22 February 
Avingtrans PLCHalf Year Results
City of London Investment Group PLCHalf Year Results
Conduit Holdings LtdFull Year Results
Hochschild Mining PLCFull Year Results (TBC)
Liberty Global PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
Primary Health Properties PLCFull Year Results
Renewables Infrastructure Group LtdFull Year Results
Rio Tinto PLCFull Year Results
Synectics PLCFull Year Results
TBC Bank Group PLCFull Year Results
Transense Technologies PLCHalf Year Results
Thursday 23 February 
Anglo American PLCFull Year Results
Arbuthnot Banking Group PLCTrading Statement
BAE Systems PLCFull Year Results
Drax Group PLCFull Year Results
Driver Group PLCFull Year Results
Genus PLCHalf Year Results
Greencoat UK Wind PLCFull Year Results (TBC)
Harmony Energy Income Trust PLCFull Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Howden Joinery Group PLCFull Year Results
Macfarlane Group PLCFull Year Results
Made Tech Group PLCHalf Year Results
Mondi PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Pantheon International PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
Serco Group PLCFull Year Results
Spectris PLCFull Year Results
Versarien PLCFull Year Results
WPP PLCFull Year Results
Friday 24 February 
ASA International Group PLCTrading Statement
CVS Group PLCHalf Year Results
European Opportunities Trust PLCHalf Year Results
Grit Real Estate Income Group LtdHalf Year Results
Irish Residential Properties REIT PLCFull Year Results
International Consolidated Airlines Group SAFull Year Results
Jupiter Fund Management PLCFull Year Results
Monday 27 February 
Associated British Foods PLCTrading Statement
Beeks Financial Cloud Group PLCHalf Year Results
Bunzl PLCFull Year Results
Centralnic Group PLCFull Year Results
Dechra Pharmaceuticals PLCHalf Year Results
DX Group PLCHalf Year Results
GlobalData PLCFull Year Results
Greencoat Renewables PLCFull Year Results
Kosmos Energy LtdFull Year Results
Quartix Technologies PLCFull Year Results
RHI Magnesita NVFull Year Results
Senior PLCFull Year Results
Tuesday 28 February 
abrdn PLCFull Year Results
Benchmark Holdings PLCQ1 Results
Bluefield Solar Income Fund LtdHalf Year Results
boohoo Group PLCFull Year Results
Cap-XX LtdHalf Year Results
Croda International PLCFull Year Results
Dalata Hotel Group PLCFull Year Results
Derwent London PLCFull Year Results
Hutchmed (China) LtdFull Year Results
Intertek Group PLCFull Year Results
Kitwave Group PLCFull Year Results
Man Group PLCFull Year Results
McBride PLCHalf Year Results
Morgan Advanced Materials PLCFull Year Results
Ocado Group PLCFull Year Results
Princess Private Equity Holding LtdFull Year Results
Rotork PLCFull Year Results
St James's Place PLCFull Year Results
S-Ventures PLCFull Year Results
Travis Perkins PLCFull Year Results
Uniphar PLCFull Year Results
Unite Group PLCFull Year Results
Videndum PLCFull Year Results
XP Power LtdFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
23 Jan 2023 09:01

Hutchmed signs drug licensing deal with Takeda for sales outside China

(Alliance News) - Hutchmed (China) Ltd on Monday said it has signed an licensing agreement with Takeda Pharmaceutical Co Ltd for the Japanese company to commercialise Hutchmed's key cancer drug outside China.

Read more
18 Jan 2023 19:03

TRADING UPDATES: Galileo confirms gold zone; Spectral hails results

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
3 Jan 2023 13:47

Hutchmed China completes enrolment for solveplenib clinical trial

(Sharecast News) - Hutchmed China announced on Tuesday that it has completed patient enrollment for 'ESLIM-01', a pivotal phase 3 clinical trial of sovleplenib for the treatment of adult patients with primary immune thrombocytopenia (ITP) in China.

Read more
3 Jan 2023 10:28

Hutchmed completes patient enrolment for ITP clinical trial in China

(Alliance News) - Hutchmed (China) Ltd on Tuesday said it has completed patient enrolment for its clinical trial exploring potential treatment therapies for adults with primary immune thrombocytopenia in China.

Read more
19 Dec 2022 19:29

TRADING UPDATES: Tekcapital's MicroSalt plans IPO in 2023

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.